DUBLIN, October 20, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan ver2016" report to their offering.
The reader will understand overall trend of Japanese biosimilar market. The report covers market situation, pipeline, major players, and challenges and forecast of this market.
The market size for generics in 2012 was about 551 billion JPY. This was about 9% of the prescription drugs market as a whole. The generics market is estimated to grow to around 778 billion JPY in 2016.
The market for biosimilars was 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were on the market by 2012. The market is expected to reach over 26 billion JPY by 2016.
Key Topics Covered:
2. Definition of biosimilar
3. Related Pharmaceutical Affairs
4. Market Size
5. Market Trends
6. Biosimilar Sales Items and Main Development Items (As of 2015)
7. Trends for Major Companies
8. Daiichi Sankyo
10. Sanwa Kagaku
11. Mochida Pharmaceutical
12. Nippon Kayaku
14. Boehringer Ingelheim
15. Future Development
16. Challenges and Forecast for Biosimilars
For more information about this report visit http://www.researchandmarkets.com/research/z6jhkb/the_overview_of
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/japan-biosimilar-market-overview-2016-biosimilars-accounted-for-approx-9-of-the-prescription-drugs-market-as-a-whole---research-and-markets-300348481.html
SOURCE Research and Markets